AstraZeneca PLC — Foreign Filer Report 2022

Mar 25, 2022

6-K 1 a0893g.htm DIRECTOR/PDMR SHAREHOLDING Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com Copyright 2022 Issuer Direct Corporation a0893g

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of March 2022

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_______

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Director/PDMR Shareholding

25 March 2022 15:30 GMT

Transaction by Person Discharging Managerial Responsibilities

AstraZeneca PLC (the Company) announced that, on 24 March 2022, an award of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to Pascal Soriot, Executive Director and Chief Executive Officer, under the terms of the AstraZeneca Performance Share Plan (AZPSP).

The AZPSP award was granted on 24 March 2017 and was subject to a three-year performance period. On the third anniversary of grant the award was placed in a two-year holding period. The award vested at the end of that holding period. Application of the performance measures specified at the time of grant resulted in 97% of the AZPSP award vesting and the remaining unvested part lapsing.

Following the reinvestment of dividends accrued during performance and holding periods of the AZPSP award, and the withholding of shares to satisfy certain tax obligations arising on vesting, Mr Soriot's beneficial interests in Ordinary Shares changed as detailed in the table below:

PDMR	Ordinary Shares acquired under the AZPSP
Pascal
Soriot	129,784

For tax purposes, the fair market value of an Ordinary Share at vest of the AZPSP award was 9,730 pence, being the closing price on the last trading day preceding the vesting.

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018.

| 1 — a) | Details of the person discharging managerial responsibilities /
person closely associated — Name | Pascal
Soriot | |
| --- | --- | --- | --- |
| 2 | Reason for the notification | | |
| a) | Position/status | Chief
Executive Officer | |
| b) | Initial notification /Amendment | Initial
notification | |
| 3 | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | AstraZeneca
PLC | |
| b) | LEI | PY6ZZQWO2IZFZC3IOL08 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted | | |
| a) | Description of the financial instrument, type of
instrument Identification
code | Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292 | |
| b) | Nature of the transaction | Acquisition
of ordinary shares pursuant to a vesting under the AstraZeneca
Performance Share Plan, for nil consideration. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | | 0 | 129,784 |
| d) | Aggregated information - Aggregated volume - Price | Not applicable - single transaction | |
| e) | Date of the transaction | 24
March 2022 | |
| f) | Place of the transaction | Outside
a trading venue | |

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca .

Contacts

For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .

Adrian Kemp

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 25 March 2022

| By: /s/
Adrian Kemp |
| --- |
| Name:
Adrian Kemp |
| Title:
Company Secretary |

page break